But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $70 from $80 and keeps an Overweight rating on the shares. The ...

Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Intellia Therapeutics (NASDAQ: NTLA) announced some positive new clinical trial data only to see its stock slide by 18% -- ...

Cash runway is not expected to get Intellia to meaningful data readouts for their Phase III trials. See why NTLA stock is a ...

Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on ...

Lead candidates NTLA-2001 and NTLA-2002 achieved significant clinical milestones. Intellia Therapeutics reported ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.